Shaymaa W El-Far1,2, Maged W Helmy1,3, Sherine N Khattab1,4, Adnan A Bekhit1,5, Ahmed A Hussein2, Ahmed O Elzoghby1,6. 1. Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt. 2. Department of Biotechnology, Institute of Graduate Studies & Research, Alexandria University, Alexandria 21526, Egypt. 3. Department of Pharmacology & Toxicology, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt. 4. Department of Chemistry, Faculty of Science, Alexandria University, Alexandria 21321, Egypt. 5. Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt. 6. Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
Abstract
AIM: Multireservoir nanocarriers were fabricated for delivering antineoplastic drug cocktail from herbal and fungal origin. Monascus yellow pigments (MYPs), monascin and ankaflavin, were isolated from red-mold rice, and incorporated within casein micelles (CAS MCs) along with the herbal drug, resveratrol (RSV). Both drugs (MYPs and RSV) were simultaneously incorporated into the hydrophobic core of CAS MCs. Alternatively, MYPs-loaded CAS MCs were enveloped within RSV-phytosomal bilayer elaborating multireservoir nanocarriers. RESULTS: Cytotoxicity studies confirmed the superiority of multireservoir nanocarriers against MCF-7 breast cancer cells. The in vivo antitumor efficacy was revealed by reduction of the tumor volume and growth biomarkers. CONCLUSION: Multireservoir CAS nanocarriers for codelivery of both MYPs and RSV may be promising alternative to traditional breast cancer therapy.
AIM: Multireservoir nanocarriers were fabricated for delivering antineoplastic drug cocktail from herbal and fungal origin. Monascus yellow pigments (MYPs), monascin and ankaflavin, were isolated from red-mold rice, and incorporated within casein micelles (CAS MCs) along with the herbal drug, resveratrol (RSV). Both drugs (MYPs and RSV) were simultaneously incorporated into the hydrophobic core of CAS MCs. Alternatively, MYPs-loaded CAS MCs were enveloped within RSV-phytosomal bilayer elaborating multireservoir nanocarriers. RESULTS:Cytotoxicity studies confirmed the superiority of multireservoir nanocarriers against MCF-7 breast cancer cells. The in vivo antitumor efficacy was revealed by reduction of the tumor volume and growth biomarkers. CONCLUSION: Multireservoir CAS nanocarriers for codelivery of both MYPs and RSV may be promising alternative to traditional breast cancer therapy.
Authors: Sarah Mokhtar; Sherine N Khattab; Kadria A Elkhodairy; Mohamed Teleb; Adnan A Bekhit; Ahmed O Elzoghby; Marwa A Sallam Journal: Front Chem Date: 2022-03-22 Impact factor: 5.221